ACTIVE

EYED PHARMA

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result-6,9 M €+0,3 %over 1 year

Revenue10,5 M €-10,8 %over 1 year

Equity17,4 M €-23,8 %over 1 year

Workforce29,0 ETP-13,4 %over 1 year

Identity

Source · BCE/KBO

EYED PHARMA is a Public limited company incorporated in 2012. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Liège. It employs on average 29,0 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0508.599.605
Incorporation: 20/12/2012
Legal form: Public limited company
Registered office: Boulevard de Patience et Beaujonc 3 box 9
4000 Liège · WallonieSee on map
Contributed capital: 24 847 913,00 €
Latest accounts: 31/12/2025
Average workforce: 29,0 ETP

Activities (NACE)

72101Research and experimental development on natural sciences and engineering· main 72110Research and experimental development on biotechnology

Joint committees (1)

Signals

Solid equityGood liquidityHealthy social debts

Financials

Source · NBB, 14 filings

Trend over 11 financial years

	2025		2024		2023		2022		2021
Income statement
Revenue	10,5 M €	-10.8%	11,8 M €		–		–		–
EBITDA	-2,7 M €	+30.9%	-3,9 M €	-7.4%	-3,6 M €	+20.3%	-4,6 M €	-45.7%	-3,1 M €
Operating result	-8,2 M €	+1.7%	-8,3 M €	-7.1%	-7,8 M €	-5.3%	-7,4 M €	-43.5%	-5,1 M €
Net result	-6,9 M €	+0.3%	-6,9 M €	-15.0%	-6 M €	+4.4%	-6,3 M €	-34.7%	-4,7 M €
Balance sheet
Equity	17,4 M €	-23.8%	22,8 M €	-17.2%	27,5 M €	+68.9%	16,3 M €	-19.5%	20,2 M €
Total assets	50,6 M €	+19.6%	42,3 M €	+11.8%	37,9 M €	+39.7%	27,1 M €	-17.2%	32,7 M €
Cash	1,3 M €	+7.1%	1,2 M €	+17.5%	1 M €	-70.2%	3,5 M €	-74.3%	13,5 M €
Debts	33,1 M €	+69.2%	19,5 M €	+89.2%	10,3 M €	-4.1%	10,8 M €	-13.5%	12,5 M €
Other
Workforce	29,0 ETP	-13.4%	33,5 ETP	-1.5%	34,0 ETP	-15.0%	40,0 ETP	+25.0%	32,0 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 10 M€ and 25 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

9 active · 13 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Robert Taub	Director05/07/2025 → 12/06/2029
Jean Marie Rakic	Director09/05/2019 → 12/06/2029
Jean Philippe Combal	Director03/07/2025 → 12/06/2029
Marc Foidart	Director30/06/2016 → 12/06/2029Chairman of the board of directors09/05/2019 → 2024 accountsended
NOSHAQ0426.624.509Represented by Eric Brandt	Director30/06/2016 → 12/06/2029
Pierre Bellichard	Chairman of the board of directors03/07/2025 → 12/06/2029
Fund+0629.896.521Represented by Bart De Leeuw	Director20/01/2023 → 20/01/2027
CORPAR0882.017.337Represented by Baudouin Jolly	Director20/12/2021 → 16/06/2026
SPARAXIS0452.116.307Represented by Caroline Thielen	Director20/12/2021 → 16/06/2026

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Carolyn Myers	Director14/06/2022 → 2024 accounts
Denis Knoops	Director09/05/2019 → 2021 accounts

Other companies at this address

Boulevard de Patience et Beaujonc 3 4000 Liège

Company	CBE no.
Abscint● Active	0749.828.410
Aeroforge● Active	1044.274.185
AMPACIMON● Active	0827.990.317
Amyl Therapeutics● Active	0758.775.372
BECARV● Bankrupt	0840.777.885
BE.SPINE● Active	1013.110.857
CATALYA● Active	0727.648.171
CEFALY Technology● Active	0870.578.661
DERMAX● Active	0667.730.677
DIANOSIC● Active	1034.558.646
DW Cefaly Holding● Active	0725.837.241
EARTH ALIVE CLEAN TECHNOLOGIES BELGIUM● Active	1023.778.481
EXO Biologics● Active	0732.982.379
ExoXpert● Active	1003.807.666
Hirundo Biosciences● Active	0681.855.065
HolyFox Invest● Active	1010.693.181
Hyloris● Active	0669.738.676
Hyloris Developments● Active	0542.737.368
Hyloris Pharmaceuticals● Active	0674.494.151
Hyloris Therapeutics● Active	1025.029.385

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	06/10/2026	28/07/2025	17/07/2024	28/06/2023	23/08/2022	31/08/2021
General meeting	15/09/2026	03/07/2025	28/06/2024	13/06/2023	14/06/2022	20/08/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 14 filings

Model	Closing	General meeting	Filed	Language	Document
Abridged modelCorrection	31/12/2025	15/09/2026	06/10/2026	French	PDF
Abridged model	31/12/2025	15/09/2026	22/09/2026	French	PDF
Abridged model	31/12/2024	03/07/2025	28/07/2025	French	PDF
Abridged model	31/12/2023	28/06/2024	17/07/2024	French	PDF
Abridged model	31/12/2022	13/06/2023	28/06/2023	French	PDF
Abridged model	31/12/2021	14/06/2022	23/08/2022	French	PDF
Abridged model	31/12/2020	20/08/2021	31/08/2021	French	PDF
Abridged model	31/12/2019	06/08/2020	31/08/2020	French	PDF
Micro model	31/12/2018	28/06/2019	23/07/2019	French	PDF
Micro model	31/12/2017	12/06/2018	31/08/2018	French	PDF
Micro model	31/12/2016	13/06/2017	29/09/2017	French	PDF
Abridged model	31/12/2015	14/06/2016	02/08/2016	French	PDF
Abridged model	31/12/2014	09/06/2015	31/08/2015	French	PDF
Abridged model	31/12/2013	10/06/2014	25/08/2014	French	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 10 M€ and 25 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

9 active · 13 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Robert Taub	Director05/07/2025 → 12/06/2029
Jean Marie Rakic	Director09/05/2019 → 12/06/2029
Jean Philippe Combal	Director03/07/2025 → 12/06/2029
Marc Foidart	Director30/06/2016 → 12/06/2029Chairman of the board of directors09/05/2019 → 2024 accountsended
NOSHAQ0426.624.509Represented by Eric Brandt	Director30/06/2016 → 12/06/2029
Pierre Bellichard	Chairman of the board of directors03/07/2025 → 12/06/2029
Fund+0629.896.521Represented by Bart De Leeuw	Director20/01/2023 → 20/01/2027
CORPAR0882.017.337Represented by Baudouin Jolly	Director20/12/2021 → 16/06/2026
SPARAXIS0452.116.307Represented by Caroline Thielen	Director20/12/2021 → 16/06/2026

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Carolyn Myers	Director14/06/2022 → 2024 accounts
Denis Knoops	Director09/05/2019 → 2021 accounts

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

13/10/2026
—
PDF
Capital / shares28/04/2026
CAPITAL, ACTIONS
PDF
Mandates18/11/2025
DEMISSIONS, NOMINATIONS
PDF
Mandates23/11/2023
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
PDF
Mandates04/04/2023
DEMISSIONS, NOMINATIONS
PDF
Mandates24/01/2023
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
PDF
Registered office23/05/2022
SIEGE SOCIAL
PDF
Mandates27/12/2021
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts

Year

Identity

Incorporation

Name

Registered office

Annual accounts

Filings11 filings

Mandates

Robert Taub

NOSHAQ

Pierre Bellichard

Marc Foidart

Jean Marie Rakic

Jean Philippe Combal

Fund+

SPARAXIS

CORPAR

Carolyn Myers

Qbic Venture Partners II

PIENTER-JAN

Show the 10 other mandates

201220132014201520162017201820192020202120222023202420252026202720282029

EYED PHARMA

Rue Louis Plescia 9, 4102 Ougrée

Director

Chairman of the board of directors

DirectorChairman of the board of directors

Director

CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE

Registered address	Period	Source
Boulevard de Patience et Beaujonc 3 bte 9, 4000 LiègeCurrent	CBE since 07/10/2026	CBE
Rue Louis Plescia 9, 4102 Ougrée	CBE until 07/10/2026	CBE
Rue Louis Plescia 9, 4102 Ougrée	accounts 2021 → 2025	Accounts 2025 · 2026-00552095

Company names

Source · NBB annual accounts, CBE

Name	Period	Source
EYED PHARMACurrent	accounts 2021 → 2025	Accounts 2025 · 2026-00552095

Events

2025
Annual accounts 2025-6,9 M €↑
2024
Annual accounts 2024-6,9 M €↓
2023
Annual accounts 2023-6 M €↑
2022
Annual accounts 2022-6,3 M €↓
2021
Annual accounts 2021-4,7 M €↓
2018
Annual accounts 2018-1,8 M €↓
2017
Annual accounts 2017-703 k €↓
2016
Annual accounts 2016-525,7 k €↓
2015
Annual accounts 2015-212,4 k €↓
2014
Annual accounts 2014-184,9 k €↓
2013
Annual accounts 2013-50,7 k €
20/12/2012
IncorporationPublic limited company

EYED PHARMA

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline

Registered offices

Company names

Events